The HCPLive age-related macular degeneration condition center page is a comprehensive resource for clinical news and insights on retina disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for patients with AMD.
May 13th 2024
At the end of ARVO 2024, Srinivas R. Sadda, MD, became the organization's president for the 2024-2025 year. He spoke to HCPLive about his expectations for the next year in eye care.
Modified Manufacturing Process for Abicipar Shows Modest Improvement in IOI Incidence
May 22nd 2023Modified production of abicipar was linked to a moderately lower incidence and severity of IOI in nAMD eyes compared with Phase 3 results, but further reductions in IOI are required to match the incidence rates of other anti-VEGF therapies.
First-Line Bevacizumab Cost-Effective for Macular Edema Due to CRVO or HRVO
May 19th 2023An economic evaluation of the SCORE2 trial indicates aflibercept treatment was unlikely to meet most accepted standards of cost-effectiveness, due to little difference in visual acuity outcomes and a large cost differential compared with bevacizumab.
New Insight: A Changing Landscape of Retinal Therapeutics with Charles Wykoff, MD, PhD
May 10th 2023In this episode, Charles Wykoff, MD, PhD joins Dr. Sheth to provide insight into the recent landmark approval of pegcetacoplan injection (SYFOVRE™) for geographic atrophy, how clinical practice has changed as a result, and both the early struggles with and optimism for an ever-changing treatment landscape.
Ophthalmology Month in Review: April 2023
May 3rd 2023Each month, our editorial staff compiles a recap of the top news in ophthalmology from the past month. Our April 2023 month-in-review features data on the association between social determinants of health and vision loss, preferences for AMD monitoring, and the launch of a new multimedia series.
Carl Danzig, MD: Analysis of GATHER Trials Connects GA Growth with Vision Loss
April 24th 2023In an interview at ARVO 2023, Danzig discusses the post-hoc analysis from the GATHER trials, showing that a reduced rate of vision loss in patients receiving avacincaptad pegol was correlated with reduced GA growth.
New Insight: A Look at Avacincaptad Pegol with Pravin Dugel, MD
April 23rd 2023As part of our ARVO 2023 coverage, Dr. Sheth sat down with Pravin Dugel, MD, President of Iveric Bio to discuss avacincaptad pegol for geographic atrophy and a look back at Dr. Dugel's career and his transition into industry.
New Insight: The State of Retina Today, and Where We're Heading with Arshad Khanani, MD
April 13th 2023In the inaugural episode of "New Insight with Veeral Sheth, MD," Dr. Sheth speaks with Arshad Khanani, MD on exciting developments from 2022, and a look at both the conference and treatment landscape unfolding in 2023.